Q-omics provides the consensus-scored TIMP4 profile across patient tissues and cancer cell-line models. TIMP4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TIMP4 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, TIMP4 RNA expression shows 16,225 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KICH, and UVM as cancer lineages where TIMP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TIMP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TIMP4 survival associations across molecular data types. TIMP4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TIMP4 RNA expression–survival associations across cancer types. High TIMP4 expression shows unfavorable associations in HNSC, UCS, ACC, UVM and ESCA, but favorable associations in KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TIMP4 RNA expression.
This table summarizes TIMP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TIMP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TIMP4 shows lower tumor expression in KICH, THCA, HNSC, KIRP, BRCA and UCEC. The KICH box plot shows higher TIMP4 RNA expression in normal versus tumor tissue (log2 FC = −2.343, t-test p < 0.001).
This table shows molecular features associated with TIMP4 in patient tissues and cancer cell lines. In patient samples, TIMP4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TIMP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and CNS.
